Boca Grande, FL, United States of America

John Michael McCall

This inventor holds 54 USPTO granted patents and 3 published patent applications and 1 EPO patent, primarily in Pharmaceutical Inhibitors (CPC class C07D). Top assignees: Bioenergenix LLC, Reveragen Biopharma, Inc., Imago Biosciences, Inc.. Active years: 2012-2025.

USPTO Granted Patents = 54 (Patent Applications = 3)

% Patents Active = 83.3

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 3.2

ph-index = 8

Forward Citations = 213(Granted Patents)

Forward Citations (Not Self Cited) = 67(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Boca Grande, FL (US) (2012 - 2023)
Half Moon Bay, CA (US) (2023)

Company Filing History:

Reveragen Biopharma, Inc.

patents

9 out of 11

Imago Biosciences, Inc.

Centaurus Therapeutics

Albany Molecular Research, Inc.

patents

8. 1 out of 17

Cadent Therapeutics, Inc.

patents

9. 1 out of 27

Knopp Biosciences, LLC

patents

10. 1 out of 5

Knopp Neurosciences, Inc.

patents

11. 1 out of 1,327

Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V.

patents

12. 1 out of 462

Science Applications International Corporation

patents

13. 1 out of 3,688

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

14. 1 out of 1

Validus Biopharma Inc.

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

Areas of Expertise:

KDM1A Inhibitors

MCT4 Inhibitors

PASK Inhibitors

Non-Hormonal Steroid Modulators

Dihydroceramide Desaturase

Pharmaceutical Compositions

Heterocyclic Compounds

Chirally Purified Substitutes

Potassium Channel Modulators

Acid Addition Salts

Aqueous Oral Suspension

Substituted Indoles

54 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12187682 - MCT4 inhibitors for treating disease (2025-01-07),

2. 11833159 - Non-hormonal steroid modulators of NF-kB for treatment of disease (2023-12-05),

3. 11773068 - KDM1A inhibitors for the treatment of disease (2023-10-03),

4. 11771684 - Inhibitors of dihydroceramide desaturase for treating disease (2023-10-03),

5. 11724989 - MCT4 inhibitors for treating disease (2023-08-15),

6. 11690853 - Non-hormonal steroid modulators of NF-κβ for treatment of disease (2023-07-04),

7. 11661409 - Acid addition salts, compositions, and methods of treating (2023-05-30),

8. 11655226 - KDM1A inhibitors for the treatment of disease (2023-05-23),

9. 11479541 - Acid addition salts, compositions, and methods of treating thereof (2022-10-25),

10. 11471471 - Aqueous oral pharmaceutical suspension compositions (2022-10-18),

11. 11459307 - Heterocyclic compounds for the inhibition of PASK (2022-10-04),

12. 11390590 - Methods and processes for the preparation of KDM1A inhibitors (2022-07-19),

13. 11382922 - Aqueous oral pharmaceutical suspension compositions (2022-07-12),

14. 11292767 - Heterocyclic inhibitors of MCT4 (2022-04-05),

15. 11230534 - KDM1A inhibitors for the treatment of disease (2022-01-25),

Title: Innovator Spotlight: John Michael McCall

Introduction:

John Michael McCall, a prolific inventor based in Boca Grande, FL, has made a significant impact in the field of pharmaceuticals with his groundbreaking discoveries. With an impressive portfolio of 53 patents, McCall continues to push the boundaries of innovation in the treatment of various diseases.

Latest Patents:

McCall's latest patents include cutting-edge inventions such as non-hormonal steroid modulators of NF-kB for the treatment of neuromuscular diseases and inhibitors of NF-κB for the prevention of muscular wasting disease. Additionally, his work on KDM1A inhibitors shows promise in the treatment of diseases like acute myelogenous leukemia.

Career Highlights:

Throughout his career, McCall has been associated with renowned companies such as Bioenergenix LLC and Reveragen Biopharma, Inc. His contributions to these organizations have been instrumental in developing novel pharmaceuticals aimed at treating a wide range of diseases.

Collaborations:

McCall has had the privilege of collaborating with esteemed professionals in the field, including coworkers Donna Lee Romero and Michael John Clare. Together, they have combined their expertise to drive innovation and bring cutting-edge treatments to those in need.

Conclusion:

In conclusion, John Michael McCall stands out as a visionary inventor who continues to revolutionize the pharmaceutical industry with his inventive solutions. His dedication to advancing the treatment of various diseases serves as a testament to his commitment to making a positive impact on society.